Pharmafile Logo
Pharmafocus logo
Advanced Search

Roivant

Showing 5 posts of 5 posts found.

gsk_boronia_australia

GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

July 13, 2018
Medical Communications Dermavent, GSK, Roivant, tapinarof

British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ …

News
image_credit_roivant

Roivant launches two new companies amid major restructure and staff layoffs

June 26, 2018
Manufacturing and Production, Research and Development Roivant, pharma

Roivant, the global biopharmaceutical firm spearheaded by founder and CEO Vivek Ramaswamy (pictured), has announced it is to undergo a …

News
shutterstock_273326141

Roivant signs $600m licensing deal with Poxel

February 13, 2018
Manufacturing and Production, Sales and Marketing Poxel, Roivant, diabetes, imeglimin, pharma

Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s …

News
biology-think-networking-physiology-brain-anatomy-2676370

Axovant’s drug bested by placebo, shares reduced to dust

January 8, 2018
Manufacturing and Production, Research and Development Axovant, Roivant, biotech, dementia, drugs, pharma, pharmaceutical

The signs were already there for Axovant Sciences’ key drug, intepirdine, when it posted poor results from a recent study …

News
shutterstock_138095450

Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind

August 10, 2017
Sales and Marketing Roivant, SoftBank, biotech, life sciences, medicine, pharma, pharmaceuticals

In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024